Stockreport

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum [Yahoo! Finance]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive Officer, and Alexandra Balcom , Chief Finan [Read more]